Nucleotide-based Production Service
Deciphering Nucleotides
Nucleotides are compounds made up of purine/pyrimidine bases, deoxyribose/ribose, and phosphoric acid. There is one phosphate group that exists in nucleoside monophosphate (NMP). The 5'-nucleotide phosphate group can be further phosphorylated to generate nucleoside diphosphate (NDP) and nucleoside triphosphate (NTP), and the phosphate groups are linked by high-energy bonds.
Biological Background of Nucleotides
Nucleotides are the precursors of biological macromolecules DNA, RNA, and participate in the heredity, developmental, and growth activities of organisms as the constituent parts of nucleic acids. In addition, many nucleotides are involved in various important biological functions, such as adenosine triphosphate (ATP), coenzymes, and others related to energy metabolism. Some nucleotide derivatives can interfere with nucleotide metabolism and have broad application prospects as anticancer drugs.
Fig.1 Chemical structures of NMP, NDP, and NTP. (CD BioGlyco)
Key Technologies
We deploy integrated chemical and enzymatic methodologies to advance nucleotide synthesis. Our platform synthesizes nucleotides through solution-phase and solid-supported techniques. A pivotal innovation involves single-step condensation reactions that circumvent conventional multi-step synthetic routes. This approach utilizes specialized reagents to construct sugar-nucleotides from commercial precursors with exceptional regioselectivity.
Biocatalytic transformations further expand our capabilities. While typically restricted to natural substrates, our enzymatic processes enable gram-scale nucleotide production. We integrate high-concentration multi-enzyme cascades with selective precipitation purification, a chromatography-free strategy optimized for industrial-scale throughput. This synergistic fusion of chemical precision and enzymatic efficiency empowers us to tackle diverse nucleoside analogs and synthetically challenging targets.
Scale with Precision: Nucleotides Perfected
In the spirit of quality first, service first, CD BioGlyco is committed to producing various high-purity nucleotides for customers. We have NMP, NDP, and NTP production services, as well as nucleotide derivative production services according to your specific needs.
There is one phosphate group in the NMP molecule. Guanosine monophosphate (GMP) has a taste property, with the ability to be a condiment. Milk powder is rich in NMP, which plays a role in improving the immunomodulatory capacity and memory of infants. We deliver end-to-end synthesis of NMPs, combining enzymatic precision with scalable processes:
- Core nucleic acid NMPs: Production of Adenine, Guanine, Cytosine, Thymine, and Uracil nucleotides via multi-enzyme cascades, achieving high-purity for specialized analogs like pseudouridine monophosphate.
- Non-nucleic acid NMPs: Synthesis of functional nucleotides, including Cyclic Adenosine Monophosphate (cAMP), Cyclic Guanosine Monophosphate (cGMP), Flavin Adenine Dinucleotide (FAD), Flavin Mononucleotide (FMN), Nicotinamide Adenine Dinucleotide(NAD), Nicotinamide Adenine Dinucleotide Phosphate (NADP), and Guanosine Pentaphosphate (pppGpp) uses optimized kinase pathways and ATP regeneration systems. Our platform supports quantitative conversions for applications in cell signaling and metabolic engineering.
NDP is obtained by adding a high-energy bonded phosphate group to NMP. ADP is a component of Coenzyme I/II. UDP is mainly used as an activated intermediate, such as UDP-glucose and CDP-ethanolamine.
NTP with three phosphate groups in the molecule is the universal energy currency. ATP is the most common; UTP functions in glycogen synthesis, CTP provides energy in phospholipid synthesis, and GTP plays a role in protein synthesis.
Nucleotide derivatives are of great value in various fields. Their powerful therapeutic effects have been shown in diseases such as cancer, cardiovascular disease, inflammation, and viral infection. In addition, they also have extensive and stable nutritional and health care functions.
Workflow
- Substrate Preparation
Prepare nucleoside and sugar substrates by dissolving them in appropriate buffers (e.g., phosphate buffer) at optimal concentrations, ensuring purity through filtration or chromatography if necessary.
- Enzyme Selection and Activation
Select specific glycosyltransferases or nucleotidyltransferases (depending on the target nucleoside-sugar) and activate them by reconstituting in a buffer with cofactors to initiate catalytic activity.
- Reaction Mixture Setup
Combine the prepared nucleoside, sugar, activated enzyme, and cofactors in a reaction vessel, adjusting pH and temperature to match the enzyme's optimal conditions.
- Incubation and Monitoring
Incubate the mixture under controlled conditions to allow the enzymatic reaction, where the sugar moiety is transferred to the nucleoside. Monitor progress periodically using analytical techniques to track product formation.
- Reaction Termination
Stop the reaction once the desired yield is achieved by methods such as heat inactivation, adding denaturing agents, or adjusting pH to extremes.
- Purification of Product
Separate the nucleoside-sugar product from unreacted substrates, enzymes, and by-products using purification steps like column chromatography, solvent extraction, or precipitation.
- Characterization and Quantification
Confirm the identity and purity of the purified nucleoside-sugar using spectroscopic methods and quantify the yield via HPLC with a standard curve or UV-visible spectroscopy.
Publication Data
DOI.: 10.1021/acssynbio.3c00737
Journal: ACS Synthetic Biology
IF: 3.9
Published: 2024
Results: This review details advances in engineering nucleotide sugar metabolism in Saccharomyces cerevisiae to enable glycosylation of natural products. The authors propound methodologies broadening yeast's endogenous UDP-sugar repertoire, constrained strictly to UDP-glucose and UDP-galactose, through salvage avenues (exploiting exogenous sugars) and de novo routes (wherein existing nucleotides undergo enzymatic interconversions). Key challenges include overcoming feedback inhibition mechanisms (e.g., UDP-xylose suppressing UDP-glucuronic acid synthesis) and engineering promiscuous glycosyltransferases. Successful applications include producing glycosylated terpenoids (e.g., saponins, steviol glycosides) and flavonoids (e.g., scutellarin) by expressing heterologous enzymes. The work highlights yeast's potential as a chassis for synthesizing bioactive glycosides with therapeutic value.
Application
- Nucleotide analogues are widely used in the development of antiviral and anticancer drugs.
- Sugar-nucleotides are crucial intermediates for studying carbohydrate metabolism and glycoconjugate biosynthesis. They are also used as substrates for enzymatic reactions in carbohydrate synthesis.
- Naturally occurring and modified sugar-nucleotides can be used as potent enzyme inhibitors in new therapeutic research.
Advantage
- Our platform is designed for scalability, from small-scale research quantities to gram-scale production for clinical development.
- We offer a vast library of natural sugar-nucleotides and can synthesize a wide variety of structural analogues.
- Our expertise in handling both chemical and enzymatic synthesis allows us to create highly customized products to meet your specific and unique project requirements.
Frequently Asked Questions
Associated Services
Our nucleotide production delivers high-purity nucleotides tailored for therapeutic and diagnostic research. To extend their functional utility, we offer Phosphate Group-based Modification Services that engineer stability, reactivity, and targeting properties:
- Phosphate Group Production by Polar Group Service
- Phosphate Group Replacement of P-O Bond by P-N Bond Service
- Mono-, Di-, and Tri-phosphate Modification Service
- Phosphoramide-based Nucleotide Modification Service
CD BioGlyco provides Custom Carbohydrate Synthesis services and exclusive solutions for clients. If you are interested in our nucleotide-based production service or Glyco™ Synthesis Platform, please feel free to contact us for more information.
Reference
- Crowe, S.A.; et al. Advances in engineering nucleotide sugar metabolism for natural product glycosylation in Saccharomyces cerevisiae. ACS Synthetic Biology. 2024, 13(6): 1589-1599. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




